We are happy to bring on Michele Libonati to the role of Chief Operating Officer (COO) and Annette Marcantonio to the role of Vice President of Clinical Operations

Pacylex to present an update on clinical progress of PCLX-001 and Series B plans for Pacylex Pharmaceuticals at Biotech Showcase™ 2023. Presentation held on Tuesday, January 10, 2023 at 10:45am PT in the Franciscan A Room.

Pacylex Granted FDA Fast Track Designation for PCLX-001 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia First in class therapy moves closer to clinical trial of PCLX-001 in Acute Myeloid Leukemia

Pacylex Announces FDA Clearance of IND Application for PCLX-001 to Treat Acute Myeloid Leukemia First US clinical trial of PCLX-001 set to start in Acute Myeloid Leukemia (AML).

Pacylex will present at ASH 2022 that Phase I clinical trial data that PCLX-001 is safe in patients at drug levels that kill AML cell lines in vitro and patient AML cells ex vivo.

Pacylex has now safely completed 4 dose cohorts and exceeded the predicted target drug exposure levels in patients based on in vitro testing of PCLX-001 with leukemia and lymphoma patient cells and cell lines.

Pacylex announces that their lead compound, PCLX-001, is granted Orphan Drug Designation for “treatment of patients with acute myeloid leukemia" by the U.S. Food and Drug Administration (FDA).

US Department of Defense Awards $1.4 million for AML Study. This study in AML patients at MD Anderson will be the first clinical study of PCLX-001 in the US.

New data on PCLX-001 being presented at AACR showing the potential for N-myristoylation inhibition to treat for AML with in vitro and animal model data: PCLX-001 dramatically reduces AML stem cells in the bone marrow.